TY - JOUR
T1 - Fluoroquinolones in paediatrics
AU - Jafri, Hasan S.
AU - McCracken, George H.
PY - 1999/1/1
Y1 - 1999/1/1
N2 - Fluoroquinolones have a broad spectrum of activity against Gram-positive, Gram-negative, and mycobacterial organisms as well as anaerobes, Mycoplasma, Chlamydia, Ureaplasma, and Legionella spp. They have excellent oral bioavailability, with good tissue penetration, and long elimination half-lives. The experience with fluoroquinolones in paediatrics has been limited because of concerns about arthropathy, based on findings in animal models. However, there has not been a definitive fluoroquinolone-associated case of arthropathy described in the literature. We believe that there are a number of specific paediatric infections in which the clinical efficacy and tolerability of the fluoroquinolones should be further investigated. These include patients with cystic fibrosis who have repeated infections with Pseudomonas spp., patients with pseudomonal and other Gram-negative infections such as urinary tract infections and osteomyelitis, and febrile neutropenic patients. Meningeal infections caused by multiple drug-resistant Streptococcus pneumoniae and Gram-negative organisms, gastroenteritis due to enteric pathogens, and mycobacterial infections are other potential conditions where fluoroquinolones should be studied in paediatric patients.
AB - Fluoroquinolones have a broad spectrum of activity against Gram-positive, Gram-negative, and mycobacterial organisms as well as anaerobes, Mycoplasma, Chlamydia, Ureaplasma, and Legionella spp. They have excellent oral bioavailability, with good tissue penetration, and long elimination half-lives. The experience with fluoroquinolones in paediatrics has been limited because of concerns about arthropathy, based on findings in animal models. However, there has not been a definitive fluoroquinolone-associated case of arthropathy described in the literature. We believe that there are a number of specific paediatric infections in which the clinical efficacy and tolerability of the fluoroquinolones should be further investigated. These include patients with cystic fibrosis who have repeated infections with Pseudomonas spp., patients with pseudomonal and other Gram-negative infections such as urinary tract infections and osteomyelitis, and febrile neutropenic patients. Meningeal infections caused by multiple drug-resistant Streptococcus pneumoniae and Gram-negative organisms, gastroenteritis due to enteric pathogens, and mycobacterial infections are other potential conditions where fluoroquinolones should be studied in paediatric patients.
UR - http://www.scopus.com/inward/record.url?scp=0032750501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032750501&partnerID=8YFLogxK
U2 - 10.2165/00003495-199958002-00008
DO - 10.2165/00003495-199958002-00008
M3 - Article
C2 - 10553704
AN - SCOPUS:0032750501
SN - 0012-6667
VL - 58
SP - 43
EP - 48
JO - Drugs
JF - Drugs
IS - SUPPL. 2
ER -